Defense against PBM crackdowns on Mounjaro, Zepbound, and GLP-1 claims.
Long-term care (LTC) pharmacy operators face audit risk from a layered set of regulators: PBM auditors, Medicare contractor auditors (DME MAC for ancillary supplies, MAC for Part D claims), state boards of pharmacy enforcing the LTC pharmacy practice framework, and DEA on the controlled substance side.
The substantive defense framework comes back to a recurring set of LTC-specific patterns: cycle fill billing, MAR (Medication Administration Record) documentation, 72-hour emergency kit dispensing, automated dispensing cabinet management, and the underlying physician orders. Health Law Alliance defends LTC pharmacy operators across all four regulatory layers. The defense framework is one matter across all four.
Federal regulators are increasingly delegating Medicaid enforcement to the states. State Medicaid Fraud Control Units and state Attorneys General are now the primary enforcement vector for pharmacy Medicaid claims - and have grown significantly more aggressive since 2023. The defense framework starts with the state regulatory regime.
.png)
By the time the PBM sends the notice, the downstream exposure is already stacked. Here's what you're actually defending against.
Zepbound and other weight-loss-indicated GLP-1s claims routinely reimburse at $1,000 to $1,400 per fill. A 12-month look-back across 200 to 400 patients produces recoupment demands of $250K to $4M+. PBMs will also extrapolate findings across your full GLP-1 book.
OptumRx and Caremark are using GLP-1 audits as grounds for termination for cause. That designation follows you across every network and can end your Medicare Part D, Medicaid MCO, and commercial access - often within 30 days.
Compounded semaglutide and tirzepatide dispensing is a DEA / FDA / state board tripwire. A PBM finding can become a civil investigative demand, a state board complaint, or a federal healthcare fraud investigation within weeks.
Four factors make GLP-1 recoupments uniquely dangerous - and uniquely defensible, if you know where the PBM is actually vulnerable.
Our bench includes former OptumRx senior leadership and a former prosecutor. We know the audit workflow because we wrote it. This is how we dismantle it.
Within 24 hours: parse every deadline in the audit notice, place a litigation hold on the claims at issue, and preserve adjudication logs before the PBM rotates them out.
Claim-by-claim reconstruction: prescriber PA rationale, plan criteria at time of fill, BMI/A1C/comorbidity support, step-therapy chain, and compounding regulatory posture. Every flagged script gets its own defense memo.
We draft and file the written appeal, quantify the PBM's extrapolation errors, and negotiate directly with the auditor and network relations - using relationships and playbooks from our time inside the PBM.
If the PBM refuses a reasonable resolution, we file in federal court and pair the suit with regulatory defense at DEA, FDA, and the state board - so a PBM dispute does not escalate into a license action.
If any of these describe your 2024 to 2026 GLP-1 dispensing activity, you are already in the audit pool - whether or not the notice has arrived.
Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.
Recoupment Reversed
Multi-location independent pharmacy faced an OptumRx full-scope GLP-1 audit covering 2023 to 2025 semaglutide and tirzepatide claims. HLA reconstructed the PA chain for every flagged fill and documented extrapolation errors; final settlement reflected a 96% reduction.
Network Reinstated
Single-location pharmacy received a Caremark "termination for cause" tied to compounded semaglutide dispensing during the FDA shortage period. HLA's appeal brief led to full reinstatement across Caremark, SilverScript and Aetna networks without a recoupment.
State Board Closed
Compounding pharmacy was referred to the state board by an Express Scripts auditor alleging off-label tirzepatide dispensing. HLA's regulatory response demonstrated full compliance with USP 797 and FDA guidance in effect at the time; the board closed the matter with no discipline.
Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific audit.
Anthony's background as a former federal prosecutor and executive for major healthcare companies provided a level of expertise and insight that made all the difference. His deep understanding of healthcare law, particularly in litigation and compliance matters, helped navigate complex legal issues with ease.
Seven questions that come up on almost every first call.
Before you write a single page of your written response, have a privileged conversation with attorneys who have overseen 1,500+ pharmacy audits - from both sides of the table. Free, confidential, no retainer.
